introduct
pulmonari
infiltr
immunosuppress
patient
common
yield
bronchoscopi
bronchoalveolar
lavag
bal
report
clinic
impact
pneumocysti
viral
polymeras
chain
reaction
pcr
test
bal
extens
evalu
mix
immunosuppress
patient
popul
method
perform
retrospect
chart
review
immunosuppress
adult
pulmonari
infiltr
underw
bal
univers
rochest
medic
center
one
bal
per
patient
includ
compar
rate
posit
pcr
test
convent
test
investig
factor
associ
posit
pcr
test
final
assess
chang
antimicrobi
therapi
bronchoscopi
result
three
hundr
fiftynin
patient
underw
bal
patient
pneumocysti
pcr
test
viral
pcr
test
pneumocysti
identif
occur
patient
viral
speci
identif
occur
patient
pcr
test
increas
pneumocysti
identif
compar
microscopi
vs
p
viral
identif
compar
cultur
vs
p
patient
posit
pneumocysti
pcr
test
antibiot
stop
start
antipneumocysti
therapi
receiv
treatment
differ
number
patient
antibiot
stop
base
viral
pcr
test
result
discuss
pcr
test
increas
bal
yield
immunosuppress
patient
compar
convent
test
pneumocysti
identifi
pcr
may
caus
selflimit
infect
may
requir
antimicrobi
therapi
pcr
test
includ
evalu
pulmonari
infiltr
immunosuppress
patient
immunosuppress
patient
suscept
develop
infecti
noninfecti
pulmonari
diseas
flexibl
bronchoscopi
bronchoalveolar
lavag
bal
import
tool
util
diagnos
pulmonari
diseas
bal
report
identifi
infect
malign
diffus
alveolar
hemorrhag
pulmonari
alveolar
proteinosi
patient
mix
hematolog
malign
bone
marrow
transplant
recipi
heart
lung
transplant
recipi
patient
mix
immunosuppress
durat
symptom
type
durat
immunosuppress
time
bronchoscopi
use
prophylact
empir
antimicrobi
therapi
presenc
endem
infect
vari
significantli
across
popul
like
impact
report
yield
prior
studi
observ
posit
yield
bal
sampl
immunosuppress
patient
sinc
report
advanc
microbiolog
detect
via
pcr
polymeras
chain
reaction
greater
sensit
detect
pneumocysti
jiroveci
viralatyp
bacteri
etiolog
compar
convent
test
serum
betadglucan
test
pneumocysti
fungal
diseas
guidelin
recommend
test
perform
clinic
impact
pcr
test
immunosuppress
patient
undergo
bal
thoroughli
evalu
investig
impact
pcr
test
perform
immunosuppress
patient
lower
respiratori
tract
diseas
underw
bal
test
hypothes
pcr
test
would
lead
increas
bal
pneumocysti
viral
identif
compar
convent
test
hypothes
use
durat
antibiot
would
affect
yield
hypothes
viral
pcr
test
would
lead
discontinu
antibiot
pneumocysti
pcr
test
compar
result
demograph
bal
perform
patient
pcr
perform
determin
whether
pcr
test
alter
demograph
patient
undergo
bronchoscopi
immunosuppress
adult
year
old
underw
bronchoscopi
bal
univers
rochest
medic
center
identifi
use
exist
bronchoscopi
databas
institut
review
board
approv
obtain
prior
data
collect
first
bronchoscopi
per
patient
includ
nonbal
bronchoscopi
ie
bronchoalveolar
wash
exclud
patient
categor
type
immunosuppress
hivaid
hematolog
malign
solid
organ
transplant
sot
immunosuppress
solid
organ
malign
immunosuppress
chemotherapi
prednison
mg
daili
two
immunosuppress
agent
clinic
characterist
patient
document
includ
type
immunosuppress
durat
type
antimicrobi
therapi
hypoxia
feverhypothermia
complet
blood
count
presenc
new
ct
abnorm
nodul
consolid
ground
glass
opac
pneumocysti
jiroveci
identifi
use
hous
real
time
pcr
assay
target
dna
specif
pneumocysti
qualit
test
quantit
threshold
measur
dna
concentr
count
number
dna
replic
cycl
cycl
time
need
produc
detect
concentr
dna
posit
determin
base
reach
certain
dna
threshold
number
replic
cycl
requir
posit
reach
prior
replic
cycl
sampl
consid
posit
posit
reach
replic
cycl
sampl
consid
neg
fewer
replic
cycl
cycl
time
need
posit
suggest
higher
burden
start
organ
wherea
higher
replic
cycl
cycl
time
need
posit
suggest
lower
burden
start
organ
virus
identifi
use
multiplex
pcr
filmarray
biofir
identifi
virus
adenoviru
coronaviru
strain
metapneumoviru
rhinovirusenteroviru
influenza
strain
influenza
b
respiratori
syncyti
viru
parainfluenza
atyp
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
pneumocysti
jiroveci
identif
microscopi
consist
grocottgomori
methenamin
silver
stain
calcofluor
white
stain
convent
identif
virus
util
standard
cultur
techniqu
cytomegaloviru
hivaid
herp
simplex
viru
without
concomit
dissemin
candida
saccharomyc
penicillium
speci
identifi
cultur
consid
posit
antimicrobi
therapi
document
bal
chang
therapi
assess
seven
day
bal
antibiot
classifi
none
commun
acquir
pneumonia
coverag
hospit
acquir
coverag
antipneumocysti
treatment
consid
antibiot
therapi
student
ttest
anova
test
use
assess
differ
group
linear
logist
regress
analys
use
determin
associ
clinic
variabl
posit
yield
databas
manag
analys
perform
use
sa
version
sa
institut
inc
cari
nc
statist
signific
defin
p
patient
underw
bal
test
bal
pcr
test
perform
patient
pneumocysti
multiplex
clinic
characterist
document
tabl
major
patient
hematolog
malign
shift
demograph
patient
underw
bal
test
compar
number
hivaid
patient
decreas
p
number
immunosuppress
patient
increas
p
tabl
posit
bal
yield
occur
patient
infecti
tabl
nonbal
test
ie
blood
urin
cultur
posit
patient
pneumocysti
identifi
patient
tabl
patient
viru
identifi
patient
pneumocysti
identif
occur
patient
tabl
identif
higher
via
pcr
test
compar
microscopi
patient
vs
patient
p
remain
true
compar
vs
respect
p
tabl
ten
patient
hivaid
posit
via
microscopi
pcr
test
bal
sampl
tabl
posit
sputum
bal
pcr
test
occur
four
patient
two
patient
neg
sputum
pcr
test
posit
bal
pcr
test
patient
neg
sputum
bal
pcr
test
compar
bal
test
sputum
test
posit
predict
valu
neg
predict
valu
sensit
specif
patient
pair
posit
sputum
bal
pcr
test
found
cycl
time
vari
one
patient
sputum
lower
cycl
time
compar
bal
vs
anoth
patient
significantli
higher
cycl
time
sputum
compar
bal
vs
five
patient
posit
pcr
test
multipl
pathogen
requir
treatment
identifi
bal
test
pneumocysti
identifi
hivaid
patient
occur
lower
pcr
cycl
time
compar
nonhiv
test
patient
vs
p
fig
microscopi
posit
pcr
cycl
time
lower
vs
p
pcr
posit
like
found
hivaid
immunosuppress
p
multiplex
viral
pcr
bal
test
increas
detect
respiratori
virus
bal
sampl
compar
viral
cultur
patient
vs
patient
p
specif
influenza
ab
vs
p
respiratori
syncyti
viru
vs
p
differ
bal
viral
pcr
yield
base
type
immunosuppress
p
fig
durat
antibiot
p
fig
viral
cultur
identifi
cytomegaloviru
eight
nonhiv
patient
eight
patient
posit
viral
pcr
test
bal
multipl
pathogen
identifi
seven
bacteria
aspergillu
twice
five
six
patient
diagnos
influenza
receiv
influenza
vaccin
two
patient
diagnos
influenza
bal
test
nasopharyng
viral
pcr
test
without
bal
viral
pcr
test
occur
patient
five
posit
previous
report
nasopharyng
multiplex
viral
pcr
test
posit
neg
predict
valu
respect
compar
bal
viral
pcr
test
influenza
miss
twice
nasopharyng
multiplex
viral
pcr
test
detect
bal
pcr
test
univari
analysi
identifi
hivaid
p
immunosuppress
p
ground
glass
opac
ct
imag
p
associ
detect
pneumocysti
pcr
multivari
analysi
confirm
hivaid
p
immunosuppress
p
ground
glass
opac
ct
imag
p
associ
posit
pneumocysti
pcr
test
tabl
univari
analysi
also
show
hematolog
malign
p
ct
imag
primarili
nodular
diseas
p
outpati
bronchoscopi
p
associ
neg
pneumocysti
pcr
test
multivari
analysi
confirm
hematolog
malign
p
ct
imag
demonstr
primarili
nodular
diseas
p
outpati
bronchoscopi
p
independ
associ
neg
pneumocysti
pcr
test
tabl
test
perform
winter
month
associ
posit
viral
pcr
test
p
allogen
bone
marrow
transplant
p
intub
p
associ
posit
viral
pcr
viral
cultur
univari
analysi
multivari
analysi
confirm
allogen
bone
marrow
transplant
p
intub
p
fig
pneumocysti
pcr
identif
vari
base
immunosuppress
anova
p
post
hoc
test
show
pneumocysti
like
found
hiv
aid
compar
hematolog
malignaci
p
solid
organ
transplant
p
viral
pcr
identif
vari
base
immunosuppress
p
fig
antibiot
durat
influenc
pneumocysti
p
viral
pcr
p
posit
independ
associ
posit
viral
pcr
viral
cultur
tabl
chang
antimicrobi
therapi
bal
test
occur
patient
neg
bal
test
prevent
patient
receiv
antibiot
patient
antibiot
stop
antibiot
cultur
neg
infiltr
occur
patient
seventeen
patient
posit
pneumocysti
pcr
test
antibiot
stop
three
patient
die
hospit
progress
underli
diseas
patient
improv
antipneumocysti
therapi
twentythre
patient
start
antipneumocysti
therapi
posit
pcr
test
ten
patient
neg
microscopi
continu
antipneumocysti
treatment
posit
pcr
test
two
patient
receiv
treatment
pneumocysti
despit
posit
pcr
test
one
patient
die
hospit
unrel
pneumocysti
patient
follow
discharg
eleven
patient
receiv
concomit
antibiot
along
antipneumocysti
treatment
seven
patient
treatment
stop
neg
pcr
test
patient
neg
pneumocysti
pcr
test
posit
betadglucan
test
three
antipneumocysti
treatment
continu
three
patient
antipneumocysti
treatment
stop
one
patient
antipneumocysti
treatment
start
one
patient
receiv
antipneumocysti
treatment
sixtythre
patient
underw
viral
pcr
test
antibiot
day
later
differ
antibiot
stop
base
viral
pcr
test
result
patient
posit
test
patient
neg
test
p
posit
bal
viral
pcr
test
patient
antivir
therapi
start
oseltamivir
x
cidofovir
ribavirin
neg
bal
viral
test
one
patient
oseltamivir
discontinu
studi
evalu
clinic
impact
pcr
test
immunosuppress
patient
undergo
bal
influenc
pcr
test
antimicrobi
chang
immunosuppress
patient
found
addit
pcr
test
bal
fluid
increas
yield
like
identifi
pneumocysti
virus
previous
miss
convent
test
importantli
empir
treatment
antibiot
antipneumocysti
therapi
affect
pcr
yield
pneumocysti
pcr
test
also
help
limit
empir
antibiot
use
patient
posit
test
decreas
antipneumocysti
therapi
patient
neg
test
multiplex
viral
pcr
effect
antibiot
stewardship
lead
addit
specif
antivir
therapi
bal
pcr
test
improv
manag
pulmonari
infiltr
immunosuppress
patient
compar
bal
pcr
test
noninvas
viral
test
occur
less
often
patient
pneumocysti
test
occur
patient
multipl
factor
contribut
includ
infecti
concern
bronchoscopi
set
time
bronchoscopi
multiplex
pcr
test
advantag
identifi
virus
easili
cultur
ie
coronaviru
metapneumoviru
faster
analysi
compar
viral
cultur
unlik
pneumocysti
pcr
test
multiplex
pcr
measur
cycl
time
determin
viral
burden
possibl
recent
observ
discord
nasopharyng
bal
sampl
make
bal
test
reason
option
clinic
suspicion
high
viral
infect
despit
neg
noninvas
test
delay
start
oseltamavir
occur
two
patient
nonbal
test
occur
nonbal
pcr
test
help
make
diagnosi
less
help
exclud
infect
patient
posit
nonbal
pcr
test
multipl
organ
identifi
bal
microscopi
identifi
pneumocysti
primarili
aid
popul
pcr
test
increas
pneumocysti
identif
immunosuppress
group
pcr
posit
rate
vari
nonbal
test
asymptomat
healthi
adult
bal
test
sampl
immunosuppress
adult
lower
respiratori
tract
diseas
found
increas
pneumocysti
identif
use
pcr
immunosuppress
group
connect
tissu
diseas
solid
organ
transplant
chang
hivaid
identif
rate
tabl
observ
increas
may
due
immunosuppress
therapi
predispos
patient
infect
lower
burden
organ
may
explain
microscopi
typic
neg
increas
may
also
due
combin
lack
specif
prophylaxi
recommend
connect
tissu
diseas
treatment
patient
group
prophylaxi
increas
sensit
pcr
test
detect
reactiv
latent
selflimit
pneumocysti
infect
base
data
pcr
test
equival
microscopi
diagnos
exclud
pneumocysti
hivaid
patient
potenti
cost
save
measur
either
test
could
perform
bal
diagnos
exclud
pneumocysti
hivaid
guidelin
use
pcr
determin
treatment
necessari
detect
pneumocysti
current
lack
robertgangneux
et
al
maillet
et
al
found
hivaid
pneumocysti
pneumonia
lower
pcr
threshold
indic
higher
burden
organ
compar
nonhivaid
patient
deem
colon
observ
hivaid
microscopi
posit
lower
cycl
time
compar
nonhivaid
microscopi
neg
patient
fig
six
patient
pcr
posit
neg
pneumocysti
pcr
test
subsequ
bal
test
would
expect
persist
posit
colon
occur
also
one
patient
cycl
time
differ
compar
nonbal
bal
test
perform
time
larg
differ
make
use
singl
cycl
time
difficult
distinguish
treatment
necessari
think
pneumocysti
infect
may
occur
spectrum
high
pneumocysti
burden
low
cycl
time
requir
therapi
lower
burden
high
cycl
time
selflimit
process
may
requir
treatment
compar
microscopi
pcr
test
excel
exclud
diseas
durandjoli
et
al
result
found
pcr
test
neg
predict
valu
betadglucan
test
call
question
neg
predict
valu
four
patient
posit
test
neg
pcr
test
sampl
error
could
contribut
find
studi
need
evalu
pcr
cycl
time
guid
treatment
compar
betadglucan
neg
pcr
test
retrospect
interpret
manag
decis
limit
studi
includ
two
patient
treat
patient
treat
concomit
antibiot
along
antipneumocysti
therapi
four
bacteria
bal
patient
antibiot
stop
treat
antipneumocysti
therapi
posit
pcr
test
pcr
test
led
initi
antipneumocysti
therapi
patient
posit
test
result
return
approach
limit
potenti
toxic
empir
pneumocysti
treatment
think
treatment
decis
made
base
pcr
test
affect
morbid
mortal
importantli
instanc
bal
perform
pneumocysti
therapi
appear
decreas
yield
patient
pneumocysti
antitherapi
prior
test
day
still
posit
pcr
test
limit
studi
first
observ
studi
reli
data
enter
electron
medic
record
subject
data
entri
error
second
provid
discret
influenc
whether
patient
underw
bronchoscopi
everi
patient
pulmonari
infiltr
evalu
bronchoscopi
third
patient
multipl
infect
pulmonari
nonpulmonari
infect
may
affect
antimicrobi
manag
could
routin
ascertain
type
infect
greatest
concern
time
bronchoscopi
lastli
manag
decis
postbronchoscopi
often
made
multipl
differ
provid
ad
variabl
manag
prospect
evalu
need
better
defin
infect
rate
standard
microbiolog
evalu
impact
manag
decis
pulmonari
infiltr
immunosuppress
patient
common
problem
etiolog
vari
depend
degre
type
underli
immunosuppress
guidelin
current
lack
microbi
evalu
base
type
immunosuppress
radiograph
abnorm
pcr
test
bal
sampl
increas
identif
infect
previous
went
undiagnos
convent
test
allow
tailor
therapi
base
result
studi
need
help
guid
nonbal
bal
test
pursu
studi
complet
thought
microbi
evalu
clinician
remain
strongest
tool
interpret
signific
test
result
base
find
propos
pneumocysti
viral
pcr
test
noninvas
invas
includ
evalu
immunosuppress
patient
ground
glass
opac
imag
furthermor
propos
patient
posit
pneumocysti
pcr
test
may
actual
selflimit
infect
pneumocysti
infect
may
exist
spectrum
diseas
studi
hypothesi
need
combin
clinic
suspicion
pcr
test
help
tool
manag
infect
immunosuppress
patient
work
support
nation
institut
health
train
grant
none
